The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences

Diabetes, Obesity and Metabolism

Volumn 14, Issue 9, 2012, Pages 780-788

  Home, P D ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Diabetes; Insulin analogue; Insulin aspart; Insulin glulisine; Insulin lispro; Pharmacodynamics; Pharmacokinetics

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; LINJETA; RECOMBINANT HUMAN INSULIN; SHORT ACTING INSULIN; SOMATOMEDIN C; UNCLASSIFIED DRUG;

DRUG ABSORPTION; DRUG ACTIVITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MEAL; MITOGENESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84864331174     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01580.x     Document Type: Review

References (84)

1. Woerle HJ, Neumann C, Zschau S et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract 2007; 77: 280-285.
2. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-494.
3. Howey DC, Bowsher RR, Brunelle RL et al. [Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia. Clin Pharmacol Ther 1995; 58: 459-469.
4. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 1998; 21: 1904-1909.
5. Perriello G, Pampanelli S, Porcellati F et al. Insulin aspart improves meal time glycaemic control in patients with type 2 diabetes: a randomized, stratified, double-blind and cross-over trial. Diabet Med 2005; 22: 606-611.
6. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 1998; 21: 1910-1914.
7. Hompesch M, McManus L, Pohl R et al. Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin. J Diabetes Sci Technol 2008; 2: 568-571.
8. Rave K, Potocka E, Boss AH, Marino M, Costello D, Chen R. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab 2009; 11: 715-720.
9. Heinemann L, Jacques Y. Oral insulin and buccal insulin: a critical reappraisal. J Diabetes Sci Technol 2009; 3: 568-584.
10. Heinemann L, Heise T, Wahl LC et al. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med 1996; 13: 625-629.
11. Becker RH, Frick AD, Burger F, Potgieter JH, Scholtz H. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes 2005; 113: 435-443.
12. ter Braak EW, Woodworth JR, Bianchi R et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 1996; 19: 1437-1440.
13. Hedman CA, Lindström T, Arnqvist HJ. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes. Diabetes Care 2001; 24: 1120-1121.
14. von Mach MA, Brinkmann C, Hansen T, Weilemann LS, Beyer J. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. Exp Clin Endocrinol Diabetes 2002; 110: 416-419.
15. Plank J, Wutte A, Brunner G et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 2002; 25: 2053-2057.
16. Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care 2003; 26: 2027-2031.
17. Swan KL, Dziura JD, Steil GM et al. Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy. Diabetes Care 2009; 32: 240-244.
18. Heise T, Nosek L, Spitzer H et al. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab 2007; 9: 746-753.
19. Luzio S, Peter R, Dunseath GJ, Mustafa L, Owens DR. A comparison of preprandial insulin glulisine versus insulin lispro in people with type 2 diabetes over a 12-h period. Diabetes Res Clin Pract 2008; 79: 269-275.
20. Horvath K, Bock G, Regittnig W et al. Insulin glulisine, insulin lispro and regular human insulin show comparable end-organ metabolic effects: an exploratory study. Diabetes Obes Metab 2008; 10: 484-491.
21. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care 1999; 22: 801-805.
22. Mudaliar SR, Lindberg FA, Joyce M et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999; 22: 1501-1506.
23. Arnolds S, Rave K, Hövelmann U, Fischer A, Sert-Langeron C, Heise T. Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. Exp Clin Endocrinol Diabetes 2010; 118: 662-664.
24. Bolli GB, Luzio S, Marzotti S et al. Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. Diabetes Obes Metab 2011; 13: 251-257.
25. Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 1999; 55: 199-203.
26. Rave K, Klein O, Frick AD, Becker RH. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care 2006; 29: 1812-1817.
27. Gentile S, Agrusta M, Guarino G et al. Metabolic consequences of incorrect insulin administration techniques in aging subjects with diabetes. Acta Diabetol 2010; 48: 121-125.
28. Becker RH, Frick AD, Burger F, Scholtz H, Potgieter JH. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. Exp Clin Endocrinol Diabetes 2005; 113: 292-297.
29. Brange J, Ribel U, Hansen JF et al. Monomeric insulins obtained by protein engineering and their medical implications. Nature 1988; 333: 679-682.
30. Humalog [prescribing information]. Eli Lilly & Company, Indianapolis, 2009.
31. NovoLog® [package insert]. Novo Nordisk A/S, Princeton, 2010.
32. Apidra® [prescribing information]. Sanofi-Aventis, US LLC, Bridgewater, 2009.
33. Humalog. Summary of product characteristics. Eli Lilly Nederland B.V., Houten, 2011. Available from URL: Accessed 23 March 2011.
34. NovoRapid®. Summary of product characteristics. Novo Nordisk A/S, Bagsværd, 2011. Available from URL: Accessed 23 March 2011.
35. Apidra®. Summary of product characteristics. Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, 2011. Available from URL: Accessed 23 March 2011.
36. American Diabetes Association. Insulin administration. Diabetes Care 2004; 27(Suppl. 1): S106-109.
37. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402.
38. Home PD, Lindholm A, Riis A, European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 2000; 17: 762-770.
39. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000; 23: 583-588.
40. Tamás G, Marre M, Astorga R, Dedov I, Jacobsen J, Lindholm A, Insulin Aspart Study Group. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study. Diabetes Res Clin Pract 2001; 54: 105-114.
41. Valle D, Santoro D, Bates P, Scarpa L, Italian Multicentre Lispro Study Group. Italian multicentre study of intensive therapy with insulin lispro in 1184 patients with type 1 diabetes. Diabetes Nutr Metab 2001; 14: 126-132.
42. Heller SR, Colagiuri S, Vaaler S et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with type 1 diabetes. Diabet Med 2004; 21: 769-775.
43. Mathiesen ER, Kinsley B, Amiel SA, Insulin Aspart Pregnancy Study Group et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007; 30: 771-776.
44. Tubiana-Rufi N, Coutant R, Bloch J et al. Special management of insulin lispro in continuous subcutaneous insulin infusion in young diabetic children: a randomized cross-over study. Horm Res 2004; 62: 265-271.
45. DeVries JH, Lindholm A, Jacobsen JL, Heine RJ, Home PD, The Tri-Continental Insulin Aspart Study Group. A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with type 1 diabetes. Diabet Med 2003; 20: 312-318.
46. Rayman G, Profozic V, Middle M. Insulin glulisine imparts effective glycaemic control in patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76: 304-312.
47. Garg SK, Rosenstock J, Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract 2005; 11: 11-17.
48. Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004; 27: 2363-2368.
49. Chlup R, Zapletalová J, Seckar P et al. Benefits of complementary therapy with insulin aspart versus human regular insulin in persons with type 2 diabetes mellitus. Diabetes Technol Ther 2007; 9: 223-231.
50. Umpierrez GE, Smiley D, Zisman A et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 2007; 30: 2181-2186.
51. Institute for Quality and Efficiency in Health Care. Rapid-acting insulin analogues in the treatment of diabetes mellitus type 1. Executive summary 2007. Available from URL: Accessed 20 September 2010.
52. Siebenhofer A, Plank J, Berghold A et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006; 2: CD003287.
53. International Diabetes Federation. Global guideline for type 2 diabetes, 2005. Available from URL: Accessed 23 February 2012.
54. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011; 34(Suppl. 1): S11-61.
55. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13(Suppl. 1): 3-68. Available from URL: Acessed 23 February 2012.
56. Hermansen K, Dornhorst A, Sreenan S. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study. Curr Med Res Opin 2009; 25: 2601-2608.
57. Ashwell SG, Amiel SA, Bilous RW et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabet Med 2006; 23: 285-292.
58. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47: 622-629.
59. Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002; 19: 393-399 (Erratum in: Diabet Med 19: 797).
60. Dashora U, Ashwell SG, Home PD. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes. Diabetes Obes Metab 2009; 11: 680-687.
61. McNally PG, Dean JD, Morris AD, Wilkinson PD, Compion G, Heller SR. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. Diabetes Care 2007; 30: 1044-1048.
62. Davidson JA, Liebl A, Christiansen JS et al. Reduced risk of hypoglycaemia with biphasic insulin aspart 30: an individual patient data meta-analysis comparing biphasic insulin aspart 30 with biphasic human insulin 30 in patients with type 2 diabetes. Clin Ther 2009; 31: 1641-1651.
63. Malone JK, Woodworth JR, Arora V et al. Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. Clin Ther 2000; 22: 222-230.
64. Schernthaner G, Wein W, Shnawa N, Bates PC, Birkett MA. Preprandial vs. postprandial insulin lispro-a comparative crossover trial in patients with type 1 diabetes. Diabet Med 2004; 21: 279-284.
65. Yamada S, Watanabe M, Kitaoka A et al. Switching from premixed human insulin to premixed insulin lispro: a prospective study comparing the effects on glucose control and quality of life. Intern Med 2007; 46: 1513-1517.
66. Boehm BO, Vaz JA, Brøndsted L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med 2004; 15: 496-502.
67. Dreyer M, Prager R, Robinson A et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res 2005; 37: 702-707.
68. Kawamori R, Kadowaki T, Ishii H, Iwasaki M, Iwamoto Y. Efficacy and safety of insulin glulisine in Japanese patients with type 1 diabetes mellitus. Diabetes Obes Metab 2009; 11: 891-899.
69. Helms KL, Kelley KW. Insulin glulisine: an evaluation of its pharmacodynamic properties and clinical application. Ann Pharmacother 2009; 43: 658-668.
70. Bartolo PD, Pellicano F, Scaramuzza A et al. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes. Diabetes Technol Ther 2008; 10: 495-498.
71. Bode B, Weinstein R, Bell D et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care 2002; 25: 439-444.
72. Weinzimer SA, Ternand C, Howard C, Chang CT, Becker DJ, Laffel LM, Insulin Aspart Pediatric Pump Study Group. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. Diabetes Care 2008; 31: 210-215.
73. Hoogma RP, Schumicki D. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res 2006; 38: 429-433.
74. Bott U, Ebrahim S, Hirschberger S, Skovlund SE. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type 1 diabetes. Diabet Med 2003; 20: 626-634.
75. Howorka K, Pumprla J, Schlusche C et al. Dealing with ceiling baseline treatment satisfaction level in patients with diabetes under flexible, functional insulin treatment: assessment of improvements in treatment satisfaction with a new insulin analogue. Qual Life Res 2000; 9: 915-930.
76. Danne T, Råstam J, Odendahl R et al. Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes. Pediatr Diabetes 2007; 8: 278-285.
77. Ashwell SG, Bradley C, Stephens JW, Witthaus E, Home PD. Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes. Diabetes Care 2008; 31: 1112-1117.
78. Dideriksen LH, Jørgensen LN, Drejer K. Carcinogenic effect on female rats after 12 months administration of the insulin analogue B10 Asp (Abstract). Diabetes 1992; 41(Suppl. 1): A143.
79. Hamel FG, Siford GL, Fawcett J, Chance RE, Frank BH, Duckworth WC. Differences in the cellular processing of AspB10 human insulin compared with human insulin and LysB28ProB29 human insulin. Metabolism 1999; 48: 611-617.
80. Hemkens LG, Grouven U, Bender R et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52: 1732-1744.
81. Sciacca L, Cassarino MF, Genua M et al. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 2010; 53: 1743-1753.
82. Kurtzhals P, Schäffer L, Sørensen A et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.
83. Stammberger I, Seipke G, Bartels T. Insulin glulisine-a comprehensive preclinical evaluation. Int J Toxicol 2006; 25: 25-33.
84. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-1777.